A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancerAlberto Chiappori, M. S. Berger, Johnetta Blakely et al.|British Journal of Cancer|2012Cited by 51
A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).Corey J. Langer, M. S. Berger, István Albert et al.|Journal of Clinical Oncology|2011Cited by 19